Alphaviruses in Gene Therapy
2009

Alphaviruses in Gene Therapy

publication Evidence: moderate

Author Information

Author(s): Kenneth Lundstrom

Primary Institution: PanTherapeutics, Lutry, Switzerland

Conclusion

Alphavirus vectors have shown versatility in gene therapy applications, particularly in vaccine development and cancer therapy.

Supporting Evidence

  • Alphavirus vectors have been engineered for efficient gene delivery and expression.
  • Clinical trials have shown that encapsulated SFV particles can be safely administered to cancer patients.
  • Alphaviruses have demonstrated high-level transient gene expression, making them suitable for vaccine production.

Takeaway

Alphaviruses can be used to help treat diseases by delivering genes into cells, especially for vaccines and cancer treatments.

Methodology

The review discusses various applications of alphavirus vectors in gene therapy, including their use in vaccines and cancer treatment, and summarizes findings from multiple studies.

Potential Biases

The review may be biased towards the positive aspects of alphavirus vectors, as it primarily discusses their applications and successes.

Limitations

Alphavirus vectors have a transient expression profile, which limits their effectiveness for chronic diseases requiring long-term treatment.

Digital Object Identifier (DOI)

10.3390/v1010013

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication